查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1996599

患者来源异质骨移植（PDX）模型市场：按类型、肿瘤类型、研究类型、移植方法、应用和最终用户划分－2026-2032年全球市场预测

Patient-Derived Xenograft/PDX Model Market by Type, Tumor Type, Study Type, Implantation Method, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，患者来源异质骨移植(PDX) 模型市场价值将达到 5.9744 亿美元，到 2026 年将成长至 6.7851 亿美元，到 2032 年将达到 15.9133 亿美元，年复合成长率为 15.02%。

主要市场统计数据
基准年 2025 5.9744亿美元
预计年份：2026年 6.7851亿美元
预测年份：2032年 1,591,330,000 美元
复合年增长率 (%) 15.02%

这是一本权威的关于患者来源异种移植 (PDX) 模型、其转化意义及其在临床前肿瘤学研究中不断演变的作用的入门书籍。

患者来源的异种移植（PDX）模型在转化肿瘤学中日益重要，因为它们能够保留患者肿瘤的结构、细胞异质性以及与相关微环境的相互作用——这些特性在传统细胞株中往往会丢失。透过将新鲜的人类肿瘤组织块移植到免疫力缺乏的囓齿动物体内，研究人员可以获得更真实反映临床疾病的模型，保留分子特征和药物反应模式。这种高度的逼真性使其在药物疗效测试、作用机制研究和生物标记开发中效用，从而弥合了临床前研究与临床假设之间的差距。

从先进的分子分析到新型移植技术和协作资料框架：正在重塑 PDX 生态系统的技术和策略转折点。

在技​​术创新和学术界、生物製药公司以及受託研究机构(CRO) 之间战略重点转变的共同推动下，PDX 领域正经历着一场变革。高解析度分子工具，例如单细胞定序和全面的基因组分析，现已常规应用于 PDX 队列，使研究人员能够详细分析肿瘤内异质性并追踪传代抗药性亚克隆。同时，基因组工程和人源化免疫系统模型正在拓展 PDX 模型检验的生物学背景，尤其是在免疫肿瘤学应用领域。

2025 年美国实施的关税将如何改变整个临床前生态系统的 PDX 供应链、采购经济和策略采购决策？

2025年实施的关税环境为依赖全球供应链维持其PDX计画的机构带来了新的营运考量。进口实验室设备、专用耗材和某些动物品系的到货成本关税增加，加速了采购审查进程，并促使许多机构重新评估筹资策略。为此，调查团队和采购负责人正在重新评估外部供应商的总拥有成本（TCO），并加强对前置作业时间和清关相关波动性的审查。

针对不同模型类型、肿瘤类别、诊断方法、移植方法和最终用户需求，细分市场的具体表现和策略挑战。

对细分市场的详细分析表明，不同模型类型、肿瘤分类、研究方法、移植途径、应用领域和最终用户的需求和性能因素各不相同。小鼠和大鼠模型之间的差异会影响实验设计，具体体现在移植存活率、免疫相容性以及对特定外科手术或原位移植的适用性等方面，从而决定疗效和转移试验的选择标准。胃肠道、妇科、血液系统、呼吸系统和泌尿系统等不同肿瘤类别的异质性会影响检体的可用性、移植存活倾向以及解读转化讯号所需的分子註释程度。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势和竞争地位正在影响进入、监管和研究伙伴关係。

区域趋势对PDX资源的取得、监管预期和合作研究网络有显着影响。美洲地区在转化肿瘤学专业知识方面特别集中，学术机构和生技公司之间形成了紧密的网络。此外，该地区也十分注重将PDX模型整合到临床转化流程中。这种环境使得临床前讯号传导和早期临床试验之间能够快速迭代，同时也推动了对可靠的分子註释和高品质生物检体的需求。

对企业定位、合作模式与能力的投资，决定了PDX模式细分市场中各相关人员之间的竞争优势。

在PDX（病患来源异种移植）研究领域，各机构之间的竞争格局日益受到能力广度、分子註释深度以及提供端到端转化服务能力的影响。领先的供应商和机构计画正在投资于整合生物银行、基因组表征和纵向体内试验的综合服务，以缩短药物研发者的决策週期。学术机构与私人实验室之间的策略伙伴关係，在扩大获取註释丰富的队列资料的同时，也分担了模型维护的成本和营运负担。

产业领导者正在采取切实有效的措施，以增强供应链韧性，加速转化价值，并优化临床前测试结果。

产业领导者可以采取以下几个具体措施来增强转换应用的影响力和营运韧性。首先，优先投资国内族群管理和冷冻保存基础设施，以减少跨境干扰的风险，同时维持遗传完整性。其次，建立统一的组织获取、移植和分子表征流程，以提高可重复性并实现有意义的队列间通讯协定。第三，将全面的基因组和单细胞分析整合到基准表征工作流程中，以便基于分子层次的见解来解读体内讯号。

为了确保分析的严谨性，我们采用了一种透明的跨学科研究方法，结合了与主要相关人员的访谈、技术检验和结构化证据整合。

本研究采用跨学科调查方法，整合了来自同行评审文献、通讯协定库以及对转化科学家、实验室主任、采购专家和合约研究组织（CRO）高管的结构化访谈的证据。主要数据透过半结构化访谈收集，以了解实际运作、挑战和策略重点，并将这些定性研究结果与技术出版物和程序标准进行检验对，以确保科学准确性。

从科学、营运和政策因素中综合洞察，这将决定 PDX倡议的短期轨迹和转化成功。

总之，当患者来源的异种移植模型被整合到严谨的分子表征流程中并透过健全的运作系统进行管理时，它们仍然是转化肿瘤学的基石。单细胞分析、免疫人源化和原位建模的科学进步正在提高PDX平台的转化保真度，而供应链压力和采购经济的变化正在促使国内能力建设和区域伙伴关係进行策略调整。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 病人异质骨移植（PDX）模型市场：按类型划分

  • 小鼠模型
  • 大鼠模型

第九章：病人异质骨移植（PDX）模型市场：依肿瘤类型划分

  • 消化器官系统
  • 妇科
  • 血液学
  • 呼吸系统
  • 泌尿器官系统

第十章：病患异质骨移植（PDX）模型市场：依研究类型划分

  • Ex-vivo
  • In-vitro
  • In-vivo

第十一章 病人来源异质骨移植（PDX）模型市场：依移植方法划分

  • 异位
  • 同域
  • 皮下

第十二章 病人异质骨移植（PDX）模型市场：依应用领域划分

  • 癌症基础调查
  • 生物标记发现
  • 基因组和分子研究
  • 个人化医疗
  • 临床前药物评价
  • 肿瘤微环境分析

第十三章 病患来源异质骨移植移植（PDX）模型市场：依最终使用者划分

  • 学术研究机构
  • 癌症研究中心
  • 製药和生物技术公司

第十四章 病人异质骨移植（PDX）模型市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章：病患异质骨移植（PDX）模型市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 病人异质骨移植（PDX）模型市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国病患异质骨移植（PDX）模型市场

第十八章：中国病人来源异质骨移植（PDX）模型市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abnova Corporation
  • Altogen Labs
  • Biocytogen
  • BioDuro LLC
  • BioReperia AB
  • Certis Oncology Solutions
  • Champions Oncology, Inc.
  • Charles River Laboratories International, Inc.
  • Creative Animodel
  • Creative Biolabs
  • Crown Bioscience by JSR Corporation
  • EPO Berlin-Buch GmbH
  • GemPharmatech Co. Ltd.
  • Genesis Drug Discovery & Development
  • Hera Biolabs
  • HOIST Co.,Ltd.
  • InnoSer
  • Inotiv, Inc.
  • Laboratory Corporation of America Holdings
  • LIDE Shanghai BIoTech, Ltd
  • Mediford Corporation by PHC Holdings Corporation
  • Oncodesign Services
  • Shanghai ChemPartner
  • Shanghai Medicilon Inc.
  • TheraIndx Lifesciences Pvt. Ltd.
  • Urosphere SAS
  • WuXi AppTec Co., Ltd.
  • Xentech
Product Code: MRR-FF1601152744

The Patient-Derived Xenograft/PDX Model Market was valued at USD 597.44 million in 2025 and is projected to grow to USD 678.51 million in 2026, with a CAGR of 15.02%, reaching USD 1,591.33 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 597.44 million
Estimated Year [2026] USD 678.51 million
Forecast Year [2032] USD 1,591.33 million
CAGR (%) 15.02%

An authoritative primer on patient-derived xenograft (PDX) models, their translational relevance, and evolving role in preclinical oncology research

Patient-derived xenograft models are increasingly central to translational oncology as they preserve patient tumor architecture, cellular heterogeneity, and relevant microenvironmental interactions that are often lost in long-established cell lines. By engrafting fresh human tumor fragments into immunocompromised rodents, researchers obtain models that retain molecular signatures and drug response patterns more representative of clinical disease. This fidelity underpins their utility across drug efficacy testing, mechanism-of-action studies, and biomarker development, providing a bridge between preclinical exploration and clinical hypotheses.

Despite their strengths, PDX platforms present distinct operational and scientific challenges. Engraftment success varies by tumor type and specimen quality, requiring refined tissue handling, optimized implantation methods, and rigorous quality-control genotyping to guard against drift. Moreover, ethical considerations and regulatory oversight demand traceability of human-derived materials and adherence to humane animal care standards. Consequently, multidisciplinary workflows that integrate surgical retrieval, pathology review, molecular profiling, and animal husbandry are essential to realize the translational promise of PDX systems.

As the field advances, investigators must balance the high biological relevance of PDX with cost, throughput, and reproducibility constraints. The most impactful programs are those that combine standardized protocols with deep molecular annotation, enabling controlled comparisons across cohorts and accelerating the translation of preclinical signals into actionable clinical strategies.

Technical and strategic inflection points reshaping the PDX ecosystem from advanced molecular profiling to novel engraftment techniques and collaborative data frameworks

The PDX landscape is undergoing transformative shifts driven by converging technological innovations and changing strategic priorities across academia, biopharma, and contract research organizations. High-resolution molecular tools such as single-cell sequencing and comprehensive genomic profiling are now routinely layered onto PDX cohorts, enabling researchers to dissect intratumoral heterogeneity and trace resistant subclones across passages. Concurrently, genome engineering and humanized immune system models are expanding the biological contexts in which PDX models can be interrogated, particularly for immuno-oncology applications.

Operationally, there is a pronounced move from isolated in-house programs toward integrated platforms that combine biobanking, molecular characterization, and longitudinal in vivo testing. This integration is reinforced by increased demand for orthotopic engraftment and sophisticated implantation strategies that better recapitulate tumor-stroma interactions and metastatic behavior. Equally important, digital infrastructure and data-sharing frameworks are maturing, allowing comparative analyses across institutions and enabling federated approaches to cohort discovery.

Together, these shifts amplify the translational value of PDX models while reshaping service models, partnership structures, and competitive dynamics. Organizations that align technical rigor with interoperable data practices and targeted clinical translation pathways will define the next generation of preclinical de-risking strategies.

How recent United States tariffs in 2025 are altering PDX supply chains, procurement economics, and strategic sourcing decisions across the preclinical ecosystem

The tariff environment introduced in 2025 has created a new set of operational considerations for organizations that rely on global supply chains to maintain PDX programs. Tariff-driven increases in the landed cost of imported laboratory equipment, specialized consumables, and certain animal strains have accelerated procurement reviews and prompted many groups to reevaluate sourcing strategies. In response, research teams and procurement specialists are reassessing the total cost of ownership for external suppliers and increasing scrutiny of lead times and customs-related variability.

Consequently, some institutions are accelerating investments in domestic breeding and cryopreservation capacity to reduce exposure to cross-border tariffs and logistic disruptions. This nearshoring trend enhances control over genetic integrity and colony health, but it requires capital allocation, expanded facility capability, and operational expertise. At the same time, there are emerging opportunities for regional vendors that can offer validated alternatives to previously imported reagents and equipment, enabling laboratories to maintain experimental continuity while managing procurement risk.

Practically, the tariff landscape has also intensified collaboration between legal, regulatory, and procurement teams to ensure compliance while preserving scientific timelines. For multinational studies and cross-border collaborations, partners are increasingly negotiating shared risk protocols and contingency plans to mitigate the operational impact of tariff-related delays and price volatility. Ultimately, the cumulative effect is a reorientation toward supply chain resilience, strategic inventory management, and strengthened supplier qualification protocols.

Segment-specific performance and strategic imperatives across model types, tumor categories, study modalities, implantation approaches and end-user demands

A granular view of segmentation reveals differentiated needs and performance drivers across types of models, tumor classes, study modalities, implantation approaches, applications, and end users. Model type distinctions between Mice Models and Rat Models shape experimental design through differences in engraftment rates, immune compatibility, and suitability for specific surgical or orthotopic procedures, thereby informing selection criteria for efficacy or metastasis studies. Tumor heterogeneity across Gastrointestinal, Gynecological, Hematological, Respiratory, and Urological categories influences specimen availability, engraftment propensity, and the degree of molecular annotation required to interpret translational signals.

Study type choices among Ex-vivo, In-vitro, and In-vivo modalities determine how PDX resources are leveraged: ex-vivo and in-vitro assays complement in-vivo efficacy testing by enabling mechanistic interrogation and medium-throughput screening, while in-vivo studies remain essential for pharmacokinetic and tumor microenvironment assessments. Implantation method selection-whether Heterotopic, Orthotopic, or Subcutaneous-directly impacts translational relevance and throughput considerations; orthotopic approaches often yield more clinically relevant metastatic and microenvironmental phenotypes, while subcutaneous implants can offer higher throughput and standardized measurement.

Applications span Basic Cancer Research, Biomarker Discovery, Genomic & Molecular Studies, Personalized Medicine, Preclinical Drug Evaluation, and Tumor Microenvironment Analysis, each imposing unique data, annotation, and sample handling requirements. Finally, end users such as Academic Research Institutes, Cancer Research Centers, and Pharmaceutical & Biotechnology Companies bring divergent priorities around throughput, regulatory traceability, and commercial confidentiality, which in turn shape service models and partnership structures across the ecosystem.

Regional dynamics and competitive positioning across the Americas, Europe, Middle East & Africa and Asia-Pacific influencing access, regulation and research partnerships

Regional dynamics are exerting a strong influence on access to PDX resources, regulatory expectations, and collaborative networks. In the Americas, there is significant concentration of translational oncology expertise, dense networks of academic centers and biotechs, and a pragmatic focus on integrating PDX models into clinical translational pipelines. This environment supports fast iteration between preclinical signals and early-phase clinical testing, while simultaneously driving demand for robust molecular annotation and high-quality biobanked specimens.

Europe, Middle East & Africa feature a heterogeneous regulatory landscape and a broad range of public research infrastructures. Pan-regional collaborations and consortia are common mechanisms to harmonize standards for human tissue use and animal welfare, and to pool rare tumor resources. These partnerships often prioritize standardized operating procedures and cross-site validation to enable multi-center preclinical programs with higher external validity.

The Asia-Pacific region combines rapid capacity expansion with growing domestic suppliers of laboratory equipment and animal models. Investment in local breeding facilities, coupled with strong clinical research activity in specific oncology indications, positions the region as both a market for services and a source of novel patient-derived material. Across all regions, regulatory alignment, data interoperability, and supplier qualification remain critical enablers of reproducible and translatable PDX-based research.

Corporate positioning, partnership patterns, and capability investments that define competitive advantage among stakeholders in the PDX model landscape

Competitive dynamics among organizations involved in PDX research are increasingly shaped by capability breadth, depth of molecular annotation, and the ability to offer end-to-end translational services. Leading providers and institutional programs are investing in integrated offerings that combine biobanking, genomic characterization, and longitudinal in vivo testing to shorten decision cycles for drug developers. Strategic partnerships between academic centers and commercial laboratories are expanding access to richly annotated cohorts while distributing the cost and operational burden of model maintenance.

Another salient trend is the prioritization of data assets. Entities that can aggregate interoperable molecular, phenotypic, and treatment-response datasets create differentiated value by enabling comparative analyses and predictive modeling. At the same time, organizations that demonstrate rigorous quality-control pipelines and transparent provenance for human-derived materials secure trust from regulatory and ethical oversight bodies, which is increasingly material in commercial collaborations. Additionally, vendors that offer scalable orthotopic modeling, immune humanization, or specialized implantation expertise are carving niche positions that align with specific therapeutic modalities, such as immuno-oncology or metastasis-focused programs.

Collectively, these strategic moves underscore that competitive advantage in the PDX domain accrues to those who combine scientific rigor with operational scalability and robust data stewardship.

Practical, high-impact actions for industry leaders to strengthen supply resilience, accelerate translational value and optimize preclinical study outcomes

Industry leaders can take several concrete steps to enhance translational impact and operational resilience. First, prioritize investments in domestic colony management and cryopreservation infrastructure to reduce exposure to cross-border disruptions while preserving genetic fidelity. Second, institutionalize harmonized protocols for tissue procurement, implantation, and molecular characterization to improve reproducibility and enable meaningful cross-cohort comparisons. Third, integrate comprehensive genomic and single-cell profiling into baseline characterization workflows so that in vivo signals can be interpreted in a molecularly informed context.

Fourth, cultivate strategic partnerships with specialized providers to access orthotopic and humanized model expertise without bearing full capital and operational overhead. Fifth, adopt federated data architectures and standardized metadata schemas to facilitate secure data sharing and comparative analyses across institutions. Sixth, engage proactively with regulatory and ethical authorities to shape pragmatic frameworks for human tissue use and animal welfare that support translational research while meeting compliance obligations. Finally, align commercial models to support translational endpoints-offering bundled services that encompass biobanking, molecular annotation, in vivo testing, and data delivery-to reduce friction for end-users and accelerate decision-making.

Transparent multidisciplinary research approach integrating primary stakeholder interviews, technical validation, and structured evidence synthesis to ensure analytic rigor

This research synthesis is grounded in a multidisciplinary methodology that triangulates evidence from peer-reviewed literature, protocol repositories, and structured interviews with translational scientists, lab directors, procurement specialists, and CRO executives. Primary data were gathered through semi-structured interviews to capture operational realities, pain points, and strategic priorities, and these qualitative insights were validated against technical publications and procedural standards to ensure scientific accuracy.

In addition, technical validation exercises reviewed representative PDX protocols and annotation practices to assess reproducibility risk and data interoperability. The segmentation approach mapped model types, tumor classes, study modalities, implantation methods, applications, and end-user profiles to identify distinct capability requirements and service gaps. Throughout the process, quality assurance checks were performed to confirm the provenance of cited methods and the currency of regulatory and ethical guidance referenced.

Limitations include sensitivity to ongoing technological developments and evolving policy landscapes, which is why the research emphasizes adaptive recommendations and encourages periodic reassessment. The methodological framework supports reproducible updating and can be tailored to incorporate new primary data or targeted deep dives on specific tumor types or geographies.

Consolidated insights synthesizing scientific, operational and policy factors that will determine the near-term trajectory and translational success of PDX initiatives

In summary, patient-derived xenograft models remain a cornerstone of translational oncology when they are embedded within rigorous molecular characterization pipelines and managed through resilient operational systems. Scientific advances in single-cell analytics, immune humanization, and orthotopic modeling are enhancing the translational fidelity of PDX platforms, while supply chain pressures and changing procurement economics are prompting strategic shifts toward domestic capability building and regional partnerships.

To realize the full potential of PDX approaches, stakeholders must balance the need for high biological relevance with considerations of throughput, cost, and reproducibility. Standardized protocols, interoperable data practices, and collaborative models that distribute infrastructure burdens will be central to this effort. Ultimately, the organizations that align technical excellence with strategic supply chain planning and clear translational pathways will be best positioned to convert preclinical insights into clinical success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Patient-Derived Xenograft/PDX Model Market, by Type

  • 8.1. Mice Models
  • 8.2. Rat Models

9. Patient-Derived Xenograft/PDX Model Market, by Tumor Type

  • 9.1. Gastrointestinal
  • 9.2. Gynecological
  • 9.3. Hematological
  • 9.4. Respiratory
  • 9.5. Urological

10. Patient-Derived Xenograft/PDX Model Market, by Study Type

  • 10.1. Ex-vivo
  • 10.2. In-vitro
  • 10.3. In-vivo

11. Patient-Derived Xenograft/PDX Model Market, by Implantation Method

  • 11.1. Heterotopic
  • 11.2. Orthotopic
  • 11.3. Subcutaneous

12. Patient-Derived Xenograft/PDX Model Market, by Application

  • 12.1. Basic Cancer Research
  • 12.2. Biomarker Discovery
  • 12.3. Genomic & Molecular Studies
  • 12.4. Personalized Medicine
  • 12.5. Preclinical Drug Evaluation
  • 12.6. Tumor Microenvironment Analysis

13. Patient-Derived Xenograft/PDX Model Market, by End-User

  • 13.1. Academic Research Institutes
  • 13.2. Cancer Research Centers
  • 13.3. Pharmaceutical & Biotechnology Companies

14. Patient-Derived Xenograft/PDX Model Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Patient-Derived Xenograft/PDX Model Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Patient-Derived Xenograft/PDX Model Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Patient-Derived Xenograft/PDX Model Market

18. China Patient-Derived Xenograft/PDX Model Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abnova Corporation
  • 19.6. Altogen Labs
  • 19.7. Biocytogen
  • 19.8. BioDuro LLC
  • 19.9. BioReperia AB
  • 19.10. Certis Oncology Solutions
  • 19.11. Champions Oncology, Inc.
  • 19.12. Charles River Laboratories International, Inc.
  • 19.13. Creative Animodel
  • 19.14. Creative Biolabs
  • 19.15. Crown Bioscience by JSR Corporation
  • 19.16. EPO Berlin-Buch GmbH
  • 19.17. GemPharmatech Co. Ltd.
  • 19.18. Genesis Drug Discovery & Development
  • 19.19. Hera Biolabs
  • 19.20. HOIST Co.,Ltd.
  • 19.21. InnoSer
  • 19.22. Inotiv, Inc.
  • 19.23. Laboratory Corporation of America Holdings
  • 19.24. LIDE Shanghai Biotech, Ltd
  • 19.25. Mediford Corporation by PHC Holdings Corporation
  • 19.26. Oncodesign Services
  • 19.27. Shanghai ChemPartner
  • 19.28. Shanghai Medicilon Inc.
  • 19.29. TheraIndx Lifesciences Pvt. Ltd.
  • 19.30. Urosphere SAS
  • 19.31. WuXi AppTec Co., Ltd.
  • 19.32. Xentech

LIST OF FIGURES

  • FIGURE 1. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY EX-VIVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY EX-VIVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY EX-VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VITRO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VITRO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VITRO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VIVO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VIVO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VIVO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HETEROTOPIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HETEROTOPIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HETEROTOPIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ORTHOTOPIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ORTHOTOPIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ORTHOTOPIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GENOMIC & MOLECULAR STUDIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GENOMIC & MOLECULAR STUDIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GENOMIC & MOLECULAR STUDIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG EVALUATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG EVALUATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG EVALUATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CANCER RESEARCH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CANCER RESEARCH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CANCER RESEARCH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 139. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 144. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. GCC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 160. G7 PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. G7 PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. G7 PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. G7 PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. G7 PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 165. G7 PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. G7 PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 167. NATO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. NATO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. NATO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. NATO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. NATO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 172. NATO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. NATO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2032 (USD MILLION)
  • TABLE 187. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)